Nutt David, Spriggs Meg, Erritzoe David
Centres for Neuropsychopharmacology and Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.
Centres for Neuropsychopharmacology and Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.
Neuropharmacology. 2023 Feb 1;223:109257. doi: 10.1016/j.neuropharm.2022.109257. Epub 2022 Sep 27.
Psychedelic therapy is perhaps the most exciting new development in psychiatry. Not only does it offer a radical new approach to treatment where mainstream approaches have proven ineffective, but the growing evidence for transdiagnostic efficacy is eliciting a re-think of current diagnostic and symptom-specific approaches to psychiatry. This excitement has led to a massive investment in this field with many tens of new pharmaceutical companies being set up to research the effects of known psychedelics and develop new patentable molecules. Whilst this enthusiasm is to be welcomed, it is important that new research is properly grounded in established facts and reflects current knowledge. In this commentary we lay out the knowledge framework that should be taken into account by all innovative researchers in this field.
迷幻疗法或许是精神病学领域最令人兴奋的新进展。它不仅为治疗提供了一种全新的激进方法,而主流方法已被证明无效,而且越来越多的跨诊断疗效证据引发了对当前精神病学诊断和症状特异性方法的重新思考。这种兴奋情绪促使该领域得到了大量投资,数十家新的制药公司纷纷成立,以研究已知迷幻剂的效果并开发新的可申请专利的分子。虽然这种热情值得欢迎,但重要的是新研究要基于既定事实并反映当前知识。在这篇评论中,我们阐述了该领域所有创新研究人员都应考虑的知识框架。